Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionSepio Capital, LP
Latest Disclosed Ownership3,752 shares
Latest Disclosed Value $ 2,898,731
Sepio Capital, LP reports 3.82% decrease in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On May 13, 2026 - Sepio Capital, LP filed a 13F-HR form disclosing ownership of 3,752 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $2,898,731 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 3,901 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of -3.82% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,752 -149 -3.82 2,899 -3.75 0.1574
2026-02-12 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,901 -79 -1.98 3,011 34.60 0.1648
2025-11-13 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 3,980 23 0.58 2,238 7.70 0.1324
2025-08-13 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 3,957 568 16.76 2,077 -3.35 0.1479
2025-05-15 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,389 842 33.06 2,150 18.47 0.1702
2025-02-13 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 2,547 -4 -0.16 1,814 -32.34 0.1452
2024-11-14 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 2,551 -19 -0.74 2,682 -0.74 0.2088
2024-08-15 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 2,570 -19 -0.73 2,701 8.39 0.2476
2024-05-15 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 2,589 -113 -4.18 2,492 5.01 0.2138
2024-02-09 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 2,702 -563 -17.24 2,373 -11.65 0.1994
2023-11-08 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 3,265 -3,718 -53.24 2,687 -46.72 0.2321
2023-08-08 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 6,983 68 0.98 5,042 -11.27 0.4094
2023-05-10 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 6,915 -411 -5.61 5,681 7.49 0.5240
2023-02-03 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 7,326 -1,295 -15.02 5,285 -11.01 0.4567
2022-10-28 2022-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 8,621 -4,800 -35.76 5,939 -25.14 0.5895
2022-07-26 2022-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 13,421 5,535 70.19 7,933 44.03 0.7969
2022-05-09 2022-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 7,886 -839 -9.62 5,508 -0.04 0.4832
2022-01-25 2021-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 8,725 -42 -0.48 5,510 3.84 0.4070
2021-11-03 2021-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 8,767 -3,566 -28.91 5,306 -22.97 0.4374
2021-07-29 2021-06-30 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 12,333 2,933 31.20 6,888 54.86 0.5674
2021-07-26 2021-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 12,333 2,933 6,888 0.5939
2021-05-10 2021-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 9,400 -55 -0.58 4,448 -2.63 0.4097
2021-02-10 2020-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 9,455 -1,528 -13.91 4,568 -25.70 0.3942
2020-11-12 2020-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 10,983 -427 -3.74 6,148 -13.60 0.6676
2020-08-04 2020-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 11,410 -348 -2.96 7,116 23.86 0.8358
2020-04-29 2020-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 11,758 309 2.70 5,745 33.64 0.7608
2020-02-06 2019-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 11,449 -1,116 -8.88 4,299 23.32 0.4067
2019-10-25 2019-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 12,565 1,880 17.59 3,486 4.25 0.3597
2019-08-08 2019-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 10,685 107 1.01 3,344 -23.02 0.4515
2019-06-21 2019-03-31 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 10,578 -1,629 -13.34 4,344 -4.72 0.5862
2019-05-14 2019-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 10,578 -1,629 4,344 0.6424
2019-02-13 2018-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 12,207 12,207 4,559 0.3314
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.